Kynam Capital Management has significantly reduced its stake in CG Oncology, selling 1,059,375 shares for approximately $43.84 million in the fourth quarter, according to a recent SEC filing. This move decreased CG Oncology’s representation in Kynam’s portfolio from 6.0% to 2.51%, leaving the fund with 945,830 shares valued at $39.27 million at the end of the quarter.

This divestment comes as CG Oncology’s stock has surged over 135% in the past year, driven by optimism surrounding its bladder cancer therapy candidate, cretostimogene, and upcoming clinical milestones. Despite this impressive price performance, the company remains in a pre-commercial phase, generating minimal revenue while facing substantial net losses. Kynam’s decision to trim its position may reflect a strategy to manage risk amid high expectations for future clinical results.

Investors should note that while CG Oncology’s strong cash position provides a buffer, the stock’s valuation is heavily reliant on the success of upcoming trials. This dynamic could lead to volatility as market sentiment adjusts to the outcomes of these critical developments.

Source: fool.com